Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 7, Issue 9, pp. 984-998
PubMed
Published By
Print ISSN
Online ISSN
History
- Received April 21, 2017
- Revision received June 1, 2017
- Accepted June 2, 2017
- Published first June 6, 2017.
Article Versions
- Previous version (June 6, 2017 - 06:02).
- Previous version (August 14, 2017 - 06:16).
- You are viewing the most recent version of this article.
Copyright & Usage
©2017 American Association for Cancer Research.
Author Information
- Olga Kondrashova1,2,
- Minh Nguyen3,
- Kristy Shield-Artin1,2,
- Anna V. Tinker4,
- Nelson N.H. Teng5,
- Maria I. Harrell6,
- Michael J. Kuiper7,
- Gwo-Yaw Ho1,2,8,
- Holly Barker1,2,
- Maria Jasin9,
- Rohit Prakash9,
- Elizabeth M. Kass9,
- Meghan R. Sullivan10,
- Gregory J. Brunette10,
- Kara A. Bernstein10,
- Robert L. Coleman11,
- Anne Floquet12,
- Michael Friedlander13,
- Ganessan Kichenadasse14,
- David M. O'Malley15,
- Amit Oza16,
- James Sun17,
- Liliane Robillard3,
- Lara Maloney3,
- David Bowtell on behalf of the AOCS Study Group18,19,20,
- Heidi Giordano3,
- Matthew J. Wakefield1,7,
- Scott H. Kaufmann21,
- Andrew D. Simmons3,
- Thomas C. Harding3,
- Mitch Raponi3,
- Iain A. McNeish22,
- Elizabeth M. Swisher6,
- Kevin K. Lin3 and
- Clare L. Scott1,2,8,*
- 1Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
- 2Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia.
- 3Clovis Oncology, Inc., Boulder, Colorado.
- 4British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
- 5Stanford University, Palo Alto, California.
- 6University of Washington, Seattle, Washington.
- 7Melbourne Bioinformatics, The University of Melbourne, Melbourne, Victoria, Australia.
- 8Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- 9Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
- 10Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
- 11The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 12Institut Bergonié, Bordeaux, France.
- 13University of New South Wales and Prince of Wales Hospital, Sydney, New South Wales, Australia.
- 14Flinders University, Adelaide, South Australia, Australia.
- 15The Ohio State University, James Cancer Center, Columbus, Ohio.
- 16Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
- 17Foundation Medicine, Inc., Cambridge, Massachusetts.
- 18Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- 19Centre for Cancer Research, University of Sydney at Westmead Millennium Institute, and Departments of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
- 20QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
- 21Mayo Clinic Cancer Center, Rochester, Minnesota.
- 22Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
- ↵*Corresponding Author:
Clare L. Scott, Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia. Phone: 61-3-9345-2498; Fax: 61-3-9347-0852; E-mail: scottc{at}wehi.edu.au
O. Kondrashova, M. Nguyen, K. Shield-Artin, K.K. Lin, and Clare L. Scott contributed equally to this article.
September 2017
Volume 7, Issue 9
Volume 7, Issue 9
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Jump to section
Advertisement